Physician profile
Abdullah Quddus
NPI 1578851515
$3,308.10
in general payments reported to CMS, 2019-2025
26 companies · $632 in 2025
The $632 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,089 · 2020: $174 · 2021: $182 · 2022: $623 · 2023: $328 · 2024: $280 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shockwave Medical, INC | $313.75 | 2022-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Edwards Lifesciences Corporation | $276.85 | 2019-2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $259.98 | 2019-2025 | Coroflow, Thoratec Heartmate 3 Lvas Implant Kit, Pressurewire |
| Abiomed | $244.41 | 2024-2025 | Impella |
| Janssen Pharmaceuticals, INC | $238.37 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $237.04 | 2019-2023 | Camzyos |
| Medtronic, INC. | $235.47 | 2022-2025 | Symplicity G3 |
| Cook Medical LLC | $225.81 | 2019-2020 | |
| Boston Scientific Corporation | $205.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.75 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $163.65 | 2019-2022 | |
| Tactile Systems Technology INC | $162.02 | 2025 | Flexitouch Plus, Nimbl |
| Siemens Medical Solutions USA, INC. | $153.82 | 2022 | |
| Imperative Care, INC | $101.32 | 2025 | Symphony Catheter |
| Amgen INC. | $97.37 | 2019-2025 | Repatha |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.35 | 2019-2020 | |
| Pfizer INC. | $31.05 | 2019 | |
| Philips North America LLC | $24.77 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $17.36 | 2019 | |
| Astellas Pharma US INC | $16.45 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.78 | 2019 | |
| Amarin Pharma, INC. | $14.49 | 2019 | |
| Chiesi USA, INC. | $14.47 | 2024 | Kengreal, Cleviprex |
| Novartis Pharmaceuticals Corporation | $12.51 | 2019 | |
| Cardiovascular Systems INC. | $12.26 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdullah Quddus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.